VSAR - Versartis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.40
-0.02 (-1.75%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.42
Open1.40
Bid1.35 x 28000
Ask1.40 x 900
Day's Range1.35 - 1.45
52 Week Range1.35 - 3.25
Volume402,769
Avg. Volume290,473
Market Cap50.737M
Beta1.06
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?
    Simply Wall St.7 days ago

    Do You Know Who Else Invests In Versartis Inc (NASDAQ:VSAR)?

    Every investor in Versartis Inc (NASDAQ:VSAR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owningRead More...

  • Associated Presslast month

    Versartis: 2Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 27 cents per share. In the final minutes of trading on Tuesday, the company's shares hit $1.78. A year ago, they were trading at $17.95. _____ ...

  • GlobeNewswirelast month

    Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments

    The transaction offers Versartis stockholders a significant ownership stake in a promising company with a novel approach for treating a variety of resistant or metastatic cancers, as well as the talent and financial resources to advance the development program to important inflection points,” said Jay Shepard, Chief Executive Officer. On June 3, 2018, Versartis and Aravive Biologics, Inc. entered into a definitive agreement under which Aravive will merge with a wholly owned subsidiary of Versartis in an all-stock transaction. The transaction has been unanimously approved by the boards of directors of both companies and is subject to approval by the stockholders of both companies.

  • Versartis Stock and Its Consistent Rise in the Week Ended June 8
    Market Realist3 months ago

    Versartis Stock and Its Consistent Rise in the Week Ended June 8

    Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.

  • ACCESSWIRE4 months ago

    Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free research report on Sarepta Therapeutics, Inc. (NASDAQ: SRPT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SRPT as the Company's latest news hit the wire. On June 01, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion against approval for EXONDYS® (eteplirsen) for treatment of patients with Duchenne muscular dystrophy (DMD).

  • ACCESSWIRE4 months ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Associated Press4 months ago

    Versartis: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 25 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $17.50. _____ This story was generated by Automated ...

  • GuruFocus.com7 months ago

    Versartis Inc (VSAR) Files 10-K for the Fiscal Year Ended on December 31, 2017

    Versartis Inc (NASDAQ:VSAR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

  • Associated Press7 months ago

    Versartis posts 4Q profit

    On a per-share basis, the Menlo Park, California-based company said it had net income of 87 cents. The biopharmaceutical company posted revenue of $40,000 in the period. For the year, the company reported ...

  • Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?
    Zacks7 months ago

    Are Options Traders Betting on a Big Move in Versartis (VSAR) Stock?

    Investors in Versartis (VSAR) need to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE10 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis

    NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...

  • TheStreet.com10 months ago

    Versartis Pops, DBV Wild Ride Continues -- Biotech Movers

    Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.

  • Associated Press11 months ago

    Versartis reports 3Q loss

    The Menlo Park, California-based company said it had a loss of $1.40 per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • 24/7 Wall St.last year

    Kroger, Versartis Locked in Monday’s 52-Week Low Club

    Kroger, Versartis Pharmaceuticals, Mattel, and Newell Brands all posted new 52-week lows on Monday.

  • Company News For Sep 25, 2017
    Zackslast year

    Company News For Sep 25, 2017

    Companies in the news are: VSAR,CAG, CMP,ICPT